𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

✍ Scribed by Robin L. Jones; David Olmos; Khin Thway; Cyril Fisher; Nina Tunariu; Sophie Postel-Vinay; Michelle Scurr; Johann de Bono; Stan B. Kaye; Ian R. Judson

Publisher
Springer
Year
2010
Tongue
English
Weight
400 KB
Volume
68
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The correlation between patient characte
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials
✍ Kevin P. Weinfurt; Liana D. Castel; Yun Li; Daniel P. Sulmasy; Andrew M. Balshem πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 105 KB

## Abstract ## BACKGROUND Patients in Phase I clinical trials sometimes report high expectations regarding the benefit of treatment. The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials. ## METH

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Understanding of an aggregate probabilit
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials
✍ Kevin P. Weinfurt; Venita DePuy; Liana D. Castel; Daniel P. Sulmasy; Kevin A. Sc πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Abstract ## BACKGROUND There is concern that patients with poor numeracy may have difficulty understanding the information necessary to make informed treatment decisions. The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participa